FST-344
FST-344, also known as Follistatin 344, is a specific form of follistatin studied primarily for its relationship with muscle regulation. Researchers are interested in how it produces circulating follistatin and influences myostatin, activin, muscle growth, and muscle function.
FST-344 AT A GLANCE
WHAT IS FST-344?
FST-344 is one of the precursor forms produced from the human follistatin gene. It contains 344 amino acids and is processed after production to create FS315, the primary form of follistatin that circulates through the bloodstream.
FST-344 belongs to the broader follistatin family, but the name identifies a particular form rather than follistatin generally. Researchers have selected FST-344 for certain muscle studies because the resulting FS315 can circulate beyond the tissue where it is produced.
HOW DOES FST-344 WORK?
FST-344 produces a form of follistatin that can bind to myostatin, activin, and other related signaling proteins. Myostatin normally helps limit skeletal-muscle growth. Reducing this signal can allow greater muscle development in experimental models.
Follistatin’s activity is more complicated than blocking myostatin alone because it can interact with several members of the transforming growth factor-beta family. This broader activity may contribute to its effects on muscle, but it also creates questions about how other tissues and biological processes could be affected.
Areas of Research
FST-344 research focuses primarily on muscle size, strength, and conditions involving progressive muscle loss. Published studies have generally examined delivery of the FST-344 gene rather than ordinary injections of a bottled follistatin product.
MUSCLE GROWTH
Examining how increased follistatin activity affects skeletal-muscle size and muscle-fiber development.
MUSCLE STRENGTH
Studying whether changes in myostatin and activin signaling influence force production and physical function.
MUSCLE LOSS
Exploring the pathway in animal models and people affected by certain muscle-wasting disorders.
GENE DELIVERY
Investigating whether a modified virus can deliver the FST-344 gene to muscle tissue and encourage local production of follistatin.
Research Highlights
Animal research using FST-344 gene delivery reported increases in muscle size and strength in mice and nonhuman primates. In the primate study, the treatment was delivered directly to the quadriceps, where researchers observed changes in the treated muscle.
A small human study delivered the FST-344 gene to the quadriceps of six people with Becker muscular dystrophy. Researchers monitored safety, muscle tissue, and walking ability. FST-344 gene therapy has also been studied in people with sporadic inclusion body myositis.
These studies involved carefully controlled gene-transfer procedures. They did not evaluate commercially available injectable FST-344 protein or establish its safety or effectiveness for muscle growth in healthy adults.
WHAT IS FST-344 MOST COMMONLY RESEARCHED FOR?
FST-344 is most commonly studied for its possible influence on skeletal-muscle growth and strength. By producing circulating follistatin, it may limit signals from myostatin and activin that help regulate muscle development. Most of this research involves animals or people with muscle disorders.
HOW DOES FST-344 FIT INTO PEPTIDE RESEARCH?
FST-344 is commonly included in peptide research libraries, but it is more accurately described as a large protein precursor rather than a short peptide. It remains relevant because it uses amino acids to influence signaling pathways also studied through experimental peptides and proteins.
WHAT MAKES FST-344 UNIQUE?
FST-344 is processed into FS315, a form of follistatin that can circulate through the bloodstream. This distinguishes it from FS288, which tends to remain more closely associated with nearby cell surfaces and tissues. Its ability to produce a circulating form helped make FST-344 a focus of experimental muscle gene-therapy studies.
HOW IS FST-344 DIFFERENT FROM GENERAL FOLLISTATIN?
Follistatin is the name of the broader regulatory protein and its related forms. FST-344 identifies a specific 344-amino-acid precursor that is processed into FS315. The general Follistatin page covers the protein’s wider roles, while this page focuses on the particular form used in muscle and gene-delivery research.
WHAT HAVE RESEARCHERS LEARNED ABOUT FST-344 SO FAR?
Animal and limited human gene-therapy research suggests that increasing FST-344 expression can affect muscle size, strength, and physical function. However, the human studies were small and involved participants with diagnosed muscle disorders. They do not establish benefits or safety for healthy people.
IS FST-344 THE SAME AS FS315?
Not exactly. FST-344 is the longer precursor sequence. A 29-amino-acid signal segment is removed during processing, producing FS315. The names describe two stages of the same protein, but they should not be treated as identical terms.
IS RESEARCH ON FST-344 CONTINUING TODAY?
Researchers continue examining follistatin and related signaling pathways in muscular dystrophy, age-related muscle loss, neuromuscular disease, and tissue development. Important questions remain about long-term safety, effects outside skeletal muscle, and whether findings from gene therapy apply to other forms of FST-344.
CAN FST-344 BE RESEARCHED ALONGSIDE OTHER PEPTIDES?
Researchers may compare FST-344 with other substances connected with muscle growth, repair, or myostatin signaling. Related research subjects include ACE-031, IGF-1 LR3, MGF, and PEG-MGF. These substances influence different pathways and should not be considered interchangeable.